Should I Wait for Retatrutide? Five Phase 3 Trials, a 2027 FDA Filing, and the Cost of Waiting
Retatrutide beat Ozempic head to head and topped 28% weight loss in trials, but approval is unlikely before late 2027. For most people, waiting costs more than it gains.
Key points
- Retatrutide is not approved anywhere; Lilly plans to file with the FDA in the first quarter of 2027, so approval is most likely between late 2027 and early 2028 under the FDA's 6- or 10-month review goals
- In TRIUMPH-1 (2,339 adults without diabetes, 80 weeks), weight fell 28.3% on 12 mg versus 2.2% on placebo if everyone stayed on treatment, or 25.0% versus 3.9% counting everyone randomized
- In TRANSCEND-T2D-2 (1,298 adults with type 2 diabetes, open-label, 80 weeks), A1C fell 2.2 points on retatrutide 9 and 12 mg versus 1.8 on Ozempic 2 mg, and weight fell 19.5% and 20.9% versus 9.4%
- No Phase 3 trial has compared retatrutide with tirzepatide; in a rough cross-trial comparison, counting everyone, retatrutide 12 mg (25.0%) leads tirzepatide 15 mg (20.9%) by about 4 points
- Stopping for side effects on 12 mg ran 11.3% in TRIUMPH-1, 13.5% in TRIUMPH-3, and 18.2% in TRIUMPH-4, versus about 4% to 5% on placebo; dysesthesia on 12 mg ranged from 6.5% to 20.9%
- Lilly has not announced a price; approved alternatives cost $149 to $449 a month self-pay as of September 2026, and Medicare's $50 Bridge lists only Wegovy, the Zepbound KwikPen, and Foundayo
- Current drugs carry proven benefits beyond weight, such as SELECT's 20% lower relative risk of heart attack, stroke, or heart death on semaglutide; retatrutide has no outcome-trial results yet
- Retatrutide sold online is not Lilly's drug: tested vials labeled 10 mg held 5.13 to 19.0 mg, and HHS's October 2026 compounding policy does not cover it
The short answer
Retatrutide is the strongest weight-loss drug Eli Lilly has tested. In its main Phase 3 obesity trial, people on the top dose lost an average of 28.3% of their body weight over 80 weeks if they stayed on the drug. On October 28, 2026, Lilly reported that it also beat Ozempic head to head in people with type 2 diabetes.
But retatrutide is not approved anywhere. Lilly plans to ask the FDA for approval in the first quarter of 2027, and an FDA review takes most of a year. That puts the earliest likely approval in late 2027, with launch, pharmacy supply, and insurance coverage coming after that.
For most people who would benefit from a weight-loss drug now, the better choice is to start an approved drug such as Zepbound or Wegovy and talk about switching once retatrutide is approved and covered. This guide covers the trial results, the side effects, the likely timeline, what waiting can cost, and the few situations where waiting may make sense.
What retatrutide is
Retatrutide is a weekly injection that acts on three hormone receptors. Like semaglutide (Ozempic, Wegovy), it activates the GLP-1 receptor, which curbs appetite and slows how fast the stomach empties. Like tirzepatide (Mounjaro, Zepbound), it also activates the GIP receptor. Unlike either drug, it activates the glucagon receptor as well. Researchers think the glucagon effect raises the energy the body burns and pushes the liver to burn more fat, but how much each receptor adds in people is not settled.
The first large human results came from a Phase 2 trial published in the New England Journal of Medicine in 2023. Among 338 adults with obesity, the 12 mg dose produced an average weight loss of 24.2% at 48 weeks, compared with 2.1% on placebo. Side effects were mostly digestive and rose with the dose. For how retatrutide compares with other drugs in development, see our triple-agonist overview.
The Phase 3 results so far
Lilly reports most results two ways. The efficacy estimand estimates the effect if everyone had stayed on the drug as assigned, while the treatment-regimen estimand counts everyone who was randomized, including people who stopped treatment early. Because the first number is usually larger, compare drugs using the same kind of number for each.
TRIUMPH-4 (December 2025). In 445 adults with obesity or overweight and knee osteoarthritis, weight fell 26.4% on 9 mg and 28.7% on 12 mg over 68 weeks, versus 2.1% on placebo. Counting everyone, the figures were 20.0% and 23.7% versus 4.6%. Knee pain scores fell about 74% to 76% on retatrutide, versus 40% on placebo.
TRIUMPH-1 (May 2026). This is the main obesity trial, and it enrolled 2,339 adults who had obesity or overweight plus at least one weight-related health problem, but no diabetes, for 80 weeks. Weight fell 19.0%, 25.9%, and 28.3% on the 4, 9, and 12 mg doses, versus 2.2% on placebo. Counting everyone, the 12 mg result was 25.0% versus 3.9%. Among people on 12 mg, 45.3% lost at least 30% of their weight. In a 104-week extension for people who started with a BMI of 35 or more, weight loss on 12 mg reached 30.3%.
TRIUMPH-2 and TRIUMPH-3 (July 2026). Both ran 80 weeks against placebo. TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and obesity or overweight. Weight fell 12.7%, 19.1%, and 20.8% on the three doses, versus 4.0% on placebo, and A1C fell by up to 1.6 percentage points from an average of 7.7%. TRIUMPH-3 enrolled 1,949 adults with a BMI of 35 or more and established heart disease. Weight fell 21.6% on 9 mg and 22.6% on 12 mg, versus 3.2% on placebo.
TRANSCEND-T2D-2 (October 2026). This was the first Phase 3 trial that compared retatrutide with a drug people already take, and it randomized 1,298 adults whose type 2 diabetes was not controlled on metformin, with or without an SGLT2 inhibitor, to retatrutide 9 mg, retatrutide 12 mg, or Ozempic 2 mg, the highest approved Ozempic dose. After 80 weeks, A1C fell 2.2 percentage points on both retatrutide doses and 1.8 points on Ozempic. Weight fell 19.5% and 20.9%, versus 9.4% on Ozempic. Because the trial was open-label, patients and their doctors knew which drug each person was taking.
Except where noted, these are efficacy-estimand figures from Lilly's press releases. Full papers, which let outside experts check the methods, are not yet out for most of these trials. No Phase 3 trial has compared retatrutide with tirzepatide.
Side effects and who stops
The most common side effects are digestive, and they become more frequent as the dose goes up. In TRIUMPH-1, nausea affected 42.4% of people on 12 mg compared with 14.8% on placebo, while vomiting affected 25.3% compared with 4.8%, and diarrhea affected 32.0% compared with 13.5%.
More people stop retatrutide than stop placebo, and the gap grows at higher doses. In TRIUMPH-1, 11.3% of people on 12 mg quit because of side effects, versus 4.9% on placebo. The 12 mg figure was 13.5% in TRIUMPH-3 and 18.2% in TRIUMPH-4. In the head-to-head diabetes trial, 7.9% quit retatrutide 12 mg, versus 2.7% for Ozempic.
Retatrutide also causes dysesthesia, an odd or painful skin sensation, more often than older drugs at their usual doses. On 12 mg, rates ranged from 6.5% in the Ozempic trial to 12.5% in TRIUMPH-1 and 20.9% in TRIUMPH-4, against about 1% on placebo. Lilly says most cases were mild to moderate. Our dysesthesia explainer covers what is known, including that the label for high-dose Wegovy reports a similar effect.
If nausea made you stop semaglutide or tirzepatide, do not assume retatrutide will be easier. Its digestive side effects were common in every trial, and some people describe fatigue as well. See our piece on fatigue on GLP-1 drugs and retatrutide.
How it compares with drugs you can get now
Comparing across trials is risky, because the people, doses, and trial lengths differ. With that warning, here are the counting-everyone results from each drug's main obesity trial: 14.9% for semaglutide 2.4 mg in STEP 1, 20.9% for tirzepatide 15 mg in SURMOUNT-1, and 25.0% for retatrutide 12 mg in TRIUMPH-1. Retatrutide looks stronger, by roughly 4 percentage points over tirzepatide in this rough comparison, but no trial has tested the two side by side.
Drugs you can start today include Zepbound (tirzepatide) as a weekly pen or vial; Wegovy (semaglutide) as a weekly pen, including a 7.2 mg high dose, or as a daily pill; and Foundayo (orforglipron), a daily pill. Each has passed FDA review and has insurance and cash-price programs in place. Zepbound is also approved for obstructive sleep apnea, and Wegovy for lowering the risk of heart attack and stroke in people with heart disease.
When retatrutide could reach you
In July 2026, Lilly said it plans to submit a Biologics License Application, the FDA filing for this kind of drug, in the first quarter of 2027, after it finishes the manufacturing section of the package. It said its data support filings for obesity, knee osteoarthritis pain, and obstructive sleep apnea.
The FDA's goal is to act on an application within 6 months under priority review or 10 months under standard review. For a new drug, that clock usually starts once the FDA accepts the filing, about two months after it arrives. So approval would most likely come between late 2027 and early 2028, followed by launch and a build-up of supply.
Insurance is the slower hurdle. Even for drugs already on the market, WTW's 2026 survey, released October 28, found that only 53% of large employers cover GLP-1 drugs for weight loss, down from 57%, and 30% of those still covering them are considering dropping coverage. Medicare's GLP-1 Bridge, which charges eligible Part D members $50 a month, names specific drugs (Wegovy, the Zepbound KwikPen, and Foundayo) and runs through December 31, 2027. A new drug would not be on that list at launch. See our employer coverage guide for more.
What it might cost
Lilly has not announced a price, but the current self-pay prices for approved weight-loss drugs give a useful reference point. As of September 2026, Zepbound through LillyDirect cost $299 a month at the starting dose and up to $449 at higher doses for people who refill on time. Foundayo cost $149 to $299 a month at most doses under prices that run through December 31, 2026. Wegovy pens cost $199 a month for the first two fills for new patients through December 31, 2026, then $349, or $399 for the 7.2 mg dose.
A drug that outperforms these could launch at a higher price, but that is our guess, not something Lilly has said. Insurers will probably require prior authorization, which is advance approval from the plan before a pharmacy can fill the prescription, and some may ask for proof that you tried an older drug first.
What waiting can cost
Waiting a year or more for retatrutide means a year or more without treatment, and the conditions that come with obesity do not pause. The benefits of current drugs also go beyond weight. In the SELECT trial, 17,604 adults with heart disease and overweight or obesity, but no diabetes, took semaglutide 2.4 mg or placebo. Over an average of 39.8 months, heart attacks, strokes, or deaths from heart disease occurred in 6.5% of people on semaglutide and 8.0% on placebo, a 20% lower relative risk. Retatrutide has no outcome results of this kind yet; Lilly lists heart and kidney outcome trials among its ongoing studies.
There is a practical point too. Most people do not stay on these drugs for years. In a Prime Therapeutics analysis of 5,780 commercially insured members without diabetes who started a GLP-1 drug for obesity, only 8% were still taking one three years later, and 14% of those who started a stronger drug such as Wegovy. Starting now, and learning how your body handles this class of drug, is useful even if you switch later.
When waiting can make sense
A few situations change the math.
You have tried semaglutide and tirzepatide and neither worked well enough. Retatrutide works partly through a different receptor, so it may help some people who did not respond. Its side effects are at least as common, though, so it is not a fix for people who stopped because of nausea.
You qualify for a clinical trial. Lilly is still running retatrutide studies. A trial gives you the study drug at no cost with close monitoring, though you may be assigned to placebo or a comparison drug. Search ClinicalTrials.gov for "retatrutide" and ask your doctor.
Your health risks are low and your goal is modest. A person with a BMI just over 27 and no diabetes, heart disease, liver disease, or sleep apnea gives up less by waiting than someone with those conditions. Even then, an approved drug can usually reach a modest goal now.
Do not buy it online
Retatrutide is already sold online as a "research" chemical. These products do not come from Lilly and are not tested for safety. A JAMA news report in October 2026 found dozens of websites selling it. When University of Queensland researchers tested three vials labeled 10 mg, they found 5.13 mg, 19.0 mg, and 16.5 mg. Victoria's health department in Australia reported six cases of acute liver injury since January 2026 in people who used products labeled retatrutide.
HHS's October 28, 2026 compounding policy covers six other peptides, not retatrutide, so pharmacies cannot legally offer it either. Our guide to retatrutide bought online has the details.
If you start now and switch later
Starting Zepbound or Wegovy now does not rule out a switch later. No trial has tested moving from one of these drugs to retatrutide, so doctors will have to plan switches case by case once it is approved. Our switching guide covers what is known about timing, and our maintenance playbook covers keeping weight off over the long term.
Corrections and updates
Correction (October 22, 2026): The original version described Prime Therapeutics' figure as roughly 8% persistence on GLP-1 therapy at three years without its scope. Prime's June 2025 analysis covered 5,780 commercially insured members without diabetes who started a GLP-1 for obesity; 8% were still taking one at three years, and 14% of those who began a higher-potency drug such as Wegovy. We added that scope.
Update and correction (October 29, 2026): We replaced the section on pending TRIUMPH-2 and TRIUMPH-3 readouts with their July 23 topline results and added TRANSCEND-T2D-2, the October 28 head-to-head trial against Ozempic 2 mg. The original version said TRIUMPH-2 included a semaglutide 1 mg comparator arm and a 52-week primary endpoint; Lilly's release describes an 80-week, placebo-controlled trial, and we corrected that.
Rewrite (October 29, 2026): Later the same day we rewrote the article from the current state of the evidence. We removed several claims we could not support with a source: that TRIUMPH-1 showed transient ALT elevations and a drop in liver fat of more than 80% (Lilly's TRIUMPH-1 release reports neither), projected launch, LillyDirect, and savings-card prices for retatrutide, a per-month estimate of lost heart benefit from waiting, discontinuation rates for SURMOUNT-1 and STEP 1, a timeline for an oral retatrutide, a 2027 readout date for a cardiovascular outcomes trial, and a link between a Lilly manufacturing investment and retatrutide. We added the approval timeline based on the FDA's review goals, side-effect and discontinuation rates from each Phase 3 release, and current self-pay prices for approved drugs.
Limitations
- Most retatrutide results come from Lilly press releases using the efficacy estimand; full peer-reviewed papers are not yet available for most Phase 3 trials
- TRANSCEND-T2D-2 was open-label and compared retatrutide with Ozempic, not tirzepatide
- Cross-trial comparisons with STEP 1 and SURMOUNT-1 involve different populations, durations, and doses and cannot show which drug is better
- The approval window is an estimate based on Lilly's stated filing plan and the FDA's general review goals; delays, a different review track, or a priority voucher could change it
- Self-pay prices for approved drugs come from manufacturer pages as of September 2026 and some offers end December 31, 2026
- This article is general information, not medical advice; the right choice depends on a person's health conditions, coverage, and history with these drugs
Citations
- 1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialPhase 2 RCT New England Journal of Medicine 2023
- 2. Once-Weekly Semaglutide in Adults with Overweight or ObesityPhase 3 RCT New England Journal of Medicine 2021
- 3. Tirzepatide Once Weekly for the Treatment of ObesityPhase 3 RCT New England Journal of Medicine 2022
- 4. Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesPhase 3 RCT New England Journal of Medicine 2023
- 5.
- 6.
- 7. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1Cpress-release Eli Lilly and Company (via BioSpace) 2026
- 8. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialpress-release Eli Lilly and Company 2026
- 9. Priority Reviewregulatory U.S. Food and Drug Administration 2026
- 10. WTW 2026 Best Practices in Healthcare Survey: U.S. employer healthcare costspress-release WTW (via GlobeNewswire) 2026
- 11. Prime Therapeutics: Leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three yearsindustry-report Prime Therapeutics 2025
- 12. Zepbound savings and self-pay pricingpricing Eli Lilly and Company 2026
- 13. Foundayo coverage and savingspricing Eli Lilly and Company 2026
- 14. What to pay for Wegovypricing Novo Nordisk 2026
- 15.
- 16. Toxicity linked to unapproved peptide product labelled Retatrutideregulatory Victorian Department of Health 2026
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.
Related insights
Maryland Caps What Public Health Plans Pay for Ozempic at $274: How State Drug Affordability Boards Work
Maryland's drug affordability board set payment limits on Ozempic and Jardiance for state and local government plans starting in 2027. Who is covered, why copays may not change, why Colorado's Enbrel limit is stuck in court, and what to ask your plan.
GLP-1 Drugs and Eating Disorders: Who May Benefit, Who Is at Risk, and the New Screening Advice
A 60-week Penn trial found semaglutide eased loss-of-control eating and body-image worries in adults with obesity, while a 45-member expert panel says people with active anorexia or restrictive bulimia should generally avoid these drugs. Semaglutide is not approved to treat binge-eating disorder.
Peptide Drugs for Alzheimer's After PRI-002's Phase 2 Miss and Semaglutide's EVOKE Failure
Priavoid's oral all-D-peptide missed its 48-week goal in a 304-person trial, with better numbers only in later, exploratory analyses. Novo Nordisk's 3,808-person semaglutide trials found no slowing at all. This guide explains both results, how their safety data relate to the approved antibodies, and how families can judge the next headline and find a trial.